Bispecific & Multispecific Antibody Development

We design and engineer bispecific antibodies, multispecific antibodies, and T cell engagers (TCEs) for immunotherapy, combining deep scientific expertise with integrated development capabilities to accelerate candidate selection, reduce development risk, and unlock therapeutic potential beyond traditional monoclonal antibodies.

We have the expertise to accelerate your bispecific or multispecific into new areas and applications.

The development of bispecific and multispecific antibodies expands therapeutic possibilities beyond traditional monoclonal antibodies. By combining multiple binding arms or incorporating additional proteins, these molecules enable bi-functional activity and improved target specificity.

Contact Us

Designing and producing bispecific antibodies can be complex, but Abzena has extensive experience in creating bispecific and multispecific formats, as well as antibody-drug conjugates (ADCs).

We recognize that every program has unique requirements. Our proven antibody design and production strategies allow rapid screening of key features such as avidity, spacing, stoichiometry, and arm formatting. This ensures efficient bispecific antibody design and development from early discovery through clinical readiness.

Our Bispecific Approach:​ Development of a Bispecific

What development stage are you at? - Abzena

There are several critical factors to consider when starting a bispecific antibody development project. Early design choices have a major impact on stability, manufacturability, and therapeutic function.

Successful bispecific antibody design should:

  • Explore multiple stoichiometries and spacing options early, regardless of the target product profile
  • Include enough bispecific constructs to confirm the desired biological functionality
  • Define a clear set of functional assays to evaluate and rank designs quickly
  • Integrate developability assessments to ensure molecules can be efficiently produced and scaled – it could be functional, but can we make it?

Rapid screening of multiple bispecific and multispecific antibody designs, even with subtle structural differences, is essential to select the most viable format for development.

​

Contact Us

Bispecific Design

Bispecific antibodies integrate multiple binding specificities into a single construct. Over time, many bispecific formats have emerged, each with unique advantages and development challenges, including freedom to operate.

If your program already uses a preferred bispecific antibody design, Abzena can support optimization and manufacturability. Where an optimal format is still under evaluation, our team offers access to a focused panel of IP-free, proven bispecific antibody formats to explore functionality and performance efficiently.

Contact Us

Bispecific Expression & Purification

One of the main challenges in bispecific antibody development is avoiding chain mispairing during expression. A common strategy to overcome this is the knob-into-hole (KiH) approach. This technique involves co-expressing two antibody heavy chains with targeted mutations that form a “knob” on one chain and a complementary “hole” on the other, promoting correct heterodimer formation.

Abzena has extensive experience in bispecific antibody design, expression, and purification. Our teams work across multiple bispecific formats, including knob-into-hole and other advanced heterodimerization technologies, to ensure high purity and functional integrity.

Contact Us

Bispecific Characterization

Because of the structural complexity of bispecific antibodies, detailed characterization and analysis are essential. Traditional analytical tools such as SDS-PAGE and SEC are often insufficient. Advanced methods like intact mass spectrometry and SEC-MALS are required to confirm correct bispecific antibody formation and purity.

Further assessments, including thermal stability profiling, provide valuable insights into molecular stability and developability. Abzena’s analytical scientists evaluate each bispecific or multispecific antibody using the most appropriate techniques to ensure reliability and reproducibility.

Characterization alone is not enough. Functional validation is critical. Working with Abzena’s bioassay team, tailored assays can be developed to confirm biological activity and support lead candidate selection.

Analytics & Bioassays

Bispecific T Cell Engagers (TCEs)

Bispecific T cell engagers (TCEs) represent a powerful class of antibody-based immunotherapies that redirect T cells to selectively recognize and destroy cancer cells. By simultaneously binding a tumor-associated antigen and a T cell receptor, typically CD3, TCEs create a synthetic immune synapse that drives targeted cell killing while offering the scalability advantages of an antibody-based therapeutic.

The promise of T cell engagers comes with significant development challenges. Molecular architecture, binding affinity, valency, geometry, Fc design, chain pairing, stability, manufacturability, and safety profiles can all influence therapeutic performance. Early design decisions are therefore critical to identifying candidates that combine strong biological activity with robust developability characteristics.

Accelerating the Development of Functional & Developable T Cell Engagers

Abzena’s T Cell Engager Expertise

Abzena applies a platform-based approach to T cell engager development, leveraging extensive experience in antibody engineering, expression, purification, characterization, and functional testing. Our scientists understand that successful T cell engager programs require more than demonstrating biological activity.

Candidates must also exhibit the stability, manufacturability, and developability needed to support progression through preclinical and clinical development.

By rapidly generating and evaluating multiple bispecific formats, valencies, geometries, and molecular architectures, we can assess how subtle design variations influence target engagement, T cell recruitment, potency, safety profile, and overall developability. This systematic approach enables informed candidate selection while reducing the risks associated with complex bispecific molecules.

Our integrated capabilities support:

  • Evaluation of multiple T cell engager formats, stoichiometries, and molecular architectures
  • Development of constructs with optimized target and CD3 engagement
  • Expression and purification strategies designed to minimize chain mispairing and maximize product quality
  • Advanced analytical characterization to assess purity, identity, stability, and developability
  • Functional bioassays that measure T cell activation, recruitment, tumor cell killing, and cytokine release profiles
  • Data-driven candidate selection to reduce development risk and accelerate progression toward clinical development

By combining deep expertise in bispecific antibody developability with integrated discovery and development capabilities, Abzena helps partners efficiently identify the most functional and developable T cell engager candidates, enabling a faster path toward clinical success.

Contact Us

Experience Across Antibody Formats

Abzena can work with you to develop the right bispecific or multispecific antibody for your application. By leveraging unparalleled expertise in antibody production, purification, analytics and functional bioassays, we can rapidly identify and advance the most promising bispecific candidates.

Whether you are at an early stage or further down the developmental path, we offer services and the necessary expertise that help to get you to the next destination.

Contact Us

Bispecific & Multispecific Antibody Development FAQs

What are bispecific antibodies?

Bispecific antibodies are engineered proteins that bind to two different antigens or epitopes at once. This dual binding improves targeting accuracy and therapeutic potential compared to traditional monoclonal antibodies.

How do bispecific antibodies differ from monoclonal antibodies?

Monoclonal antibodies target a single antigen. Bispecific antibodies engage two targets, offering enhanced therapeutic control and improved cell-to-cell interactions. This key distinction explains the difference between monoclonal antibody vs bispecific function.

Are bispecific antibodies monoclonal?

No. While both are antibody-based therapeutics, bispecific antibodies are engineered from monoclonal antibody components but have two specific binding sites instead of one.

What are multispecific antibodies?

Multispecific antibodies bind to more than two targets, offering complex therapeutic effects. These constructs extend beyond bispecific designs to support advanced immunotherapy strategies.

How does Abzena support bispecific antibody development?

Abzena provides complete support for bispecific and multispecific antibody programs, from molecular design to analytical testing and manufacturing. Our integrated services ensure efficient development and regulatory readiness.

Related Insights

An Approach to Rapidly Identify a Functional & Developable Bispecific Antibody

Learn More

EPM Article: Cell Line Development Strategies for Bispecific Antibodies

Learn More

EPM: Cell line development strategies fit for a new era of Bispecific Antibodies

Learn More
Let’s move medicine forward - Abzena

Let's work together to move your medicine forward.

We enable you to bring life-changing medicines to patients in need faster.

Contact Us Download Brochure